StockData
Genprex, Inc. logo

Genprex, Inc. (GNPX) company profile

GNPXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.67−0.23 (-12.08%)

Close on Nov 17, 2026Market cap $1.37MP/E –Yield –

About Genprex

Pharmaceutical Preparations, SIC 2834

The company is a clinical-stage biotechnology firm focused on developing gene therapies for oncology and diabetes. Its oncology pipeline relies on its proprietary ONCOPREX Delivery System, an intravenous, non-viral nanoparticle platform that carries tumor suppressor genes directly to cancer cells. The lead drug candidate, REQORSA (quaratusugene ozeplasmid), administers the TUSC2 gene and is under clinical investigation in combination with standard therapies for non-small cell lung cancer and small cell lung cancer. In diabetes, the company develops GPX-002, a preclinical candidate engineered to restore insulin generation in type 1 and type 2 diabetes. Its potential end users are patients suffering from advanced lung cancers and diabetes.

The business conducts its research and clinical operations within the United States. Its clinical pipeline includes trials across multiple medical facilities, with a planned phase 2 expansion study intended to enroll patients across 10 to 15 domestic sites. Preclinical programs and licensed technologies are researched in collaboration with academic centers, including The University of Texas MD Anderson Cancer Center and the University of Pittsburgh.

Summary of the business section of Genprex's latest annual report, written by StockData.

Company profile

Company

Legal name
Genprex, Inc.
Headquarters
Austin, TX
Address
3300 Bee Cave Road Suite 650-227 78746
Phone
(512) 537-7997
Employees
13, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Texas
Fiscal year ends
December 31
Auditor
WithumSmith+Brown, PC, East Brunswick, New Jersey

Stock & identifiers

Ticker
GNPX
Exchange
Nasdaq
IPO date
Oct 13, 2017
Shares outstanding
1M, Aug 10, 2026
Public float
$7.50M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-22 reverse, Jul 16, 2026; 1-for-50 reverse, Oct 21, 2025; 1-for-40 reverse, Feb 2, 2024; 34-for-1, Apr 17, 2018
SEC CIK
1595248
CUSIP
372446401
ISIN
US3724464017
FIGI
BBG00F7T0157
Share class FIGI
BBG00F7T0166
LEI
549300KS9771JZ234890
EIN
90-0772347

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Ryan M. ConferPresident, CEO and CFO, Director36,331
Mark Stanley BergerChief Medical Officer21,692
Brent M. LongneckerDirector9,157
William R. Wilson Jr.Director9,157
Toscano Jose Antonio MorenoDirector9,157

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Rodney Varner
$0$0$688.60K$-96–
FY2025
Ryan MConfer
$728.87K$906.31K$688.60K$-96–
FY2024
Rodney Varner
$254.74K$343.07K$500.42K$-91–
FY2024
Ryan MConfer
$541.57K$588.70K$500.42K$-91–
FY2023
Rodney Varner
$1.68M$909.63K$940.19K$-84–
FY2023
Ryan MConfer
$0$0$940.19K$-84–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOtherTotalvs. prior year
Ryan M. Confer
President, Chief Executive Officer, and Chief Financial Officer
$480.00K$96.00K$90.45K$62.42K$728.87K+35%
Mark S. Berger
Chief Medical Officer
$486.50K$97.30K$57.29K$47.52K$688.60K+25%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 13, 2017
Offer price
$5.00
Securities offered
4,500,000
Gross proceeds
$22.50M
Exchange
Nasdaq
First trading day
Mar 29, 2018
First-day close
$4.70-6.0%
Lock-up ends (est.)
Sep 25, 2018

“The initial public offering price per share is $5.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 15, 2026, we had 13 total employees, all of which were full-time.”

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 5, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 30, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 12, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 26, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 17, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 20, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 9, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 1, 2025Late filingNotification of late filing
Feb 12, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 19, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 26, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 25, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Sep 1, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 21, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 15, 2023Late filingNotification of late filing
Jul 14, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
May 16, 2023Late filingNotification of late filing
May 12, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 27, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Mar 6, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Sep 13, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 11, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 16, 2019Late filingNotification of late filing
Apr 3, 2018Late filingNotification of late filing
Oct 13, 2017IPOInitial public offering priced (424B4 prospectus)
Oct 13, 2017ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?